Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial - Rosenstock, J; Wysham, C; Frías, J P (Lancet, 2021)
et al.